NL0015285941 - Common Stock
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immatics (NASDAQ:IMTX) just reported results for the fourth quarter of 2023.Imm...
Thursday's pre-market session: top gainers and losers
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median...
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...
Biopharmaceutical company Immatics has announced an underwritten public offering of shares, without disclosing the size or terms of the offering.
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....
Immatics reports Q3 GAAP EPS of -$0.32, beating estimates by $0.07. Revenue of $5.93M misses by $6M.
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at...
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the...
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer...
/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Immatics press release (IMTX): Q2 GAAP EPS of -€0.32.Revenue of €22.4M (+30.2% Y/Y).Cash and cash equivalents as well as other financial assets not including the recent equity...
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting...
Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER®...
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2...
TCER® IMA402 ist der erste gegen die Zielstruktur PRAME gerichtete bispezifische TCR-Kandidat der nächsten Generation mit verlängerter Halbwertszeit in der...
A clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, Immatics (IMTX) stock price surged 8.3% on Monday as...
Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the...
Tübingen, Deutschland und Houston, Texas, 24. Juli 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und...